We advised venture capital fund Vsquared Ventures on investing in the biotech startup Droplet Genomics. In the late seed funding round, the startup, which from now on will be known by the name Atrandi Biosciences, raised EUR 4.5 million.
Among other investors in the company in this round were the venture capital fund Practica Capital and the investment company Meta Planet.
Established in 2016, the Lithuanian startup intends to accelerate development by setting up a team in the United States and continuing the commercialisation of droplet microfluidics and single-cell research technologies. Micro-droplet technology replaces test-tube research with droplets and can be applied in basic research or the search for new drugs.
Over the past couple of years, the founders of the company, together with Vilnius university scientists, have been working on ways to carry out high-throughput research efficiently. The company also replaced alternative capsule technology.
Our team and services
We assisted the client in preparing and negotiating the investment documentation and advised on corporate, employment and regulatory law issues. Our team also conducted legal due diligence on the target company.
Our team, led by partner Mantas Petkevičius and senior associate Matas Mačiuslaitis, consisted of senior associates Aurelija Daubaraitė and Sidas Sokolovas; as well as associates Goda Jakubauskaitė, Izabelė Petrikaitė and Simonas Šlitas.
